September 29, 2020

Volume X, Number 273

September 28, 2020

Subscribe to Latest Legal News and Analysis

Zofran Litigation Continues to Grow Across the Country

Zofran (ondansetron), manufactured by GlaxoSmithKline (GSK), is a member of a class of drugs known as 5-HT3 receptor antagonists, which work by blocking the actions of serotonin. Zofran was approved by the Food and Drug Administration (FDA) in January 1991, to treat chemotherapy-related nausea, and the approval was later expanded to treat postoperative nausea and vomiting. Since then, it has been increasingly prescribed for off-label uses, such as use by pregnant women suffering from morning sickness. Studies show that Zofran use by pregnant women can lead to a heightened risk of severe birth defects, including heart development irregularities, cleft lip and cleft palate.

In 2012, GSK agreed to pay the United States Department of Justice $3 billion to settle numerous civil and criminal allegations, including the illegal marketing of Zofran. The company is now facing lawsuits filed on behalf of children born with heart defects or craniofacial birth defects because their mothers took Zofran during pregnancy.

COPYRIGHT © 2020, STARK & STARKNational Law Review, Volume V, Number 110


About this Author

Practice Group

Stark & Stark’s Litigation group includes accomplished trial lawyers in both bench and jury trials, appeals, and administrative proceedings. They are experienced arbitrators and mediators. These lawyers are licensed in a number of jurisdictions including New Jersey, Pennsylvania, New York, Delaware, and beyond. 

We routinely litigate multi-million dollar corporate and commercial cases in multiple state and federal jurisdictions. We also serve as local counsel in complex corporate litigation matters for law firms without a presence in our...